There is an antibody-dependent enhancement (ADE) of SARS-CoV-1 infection. Notably, some vaccines enhance infection. – The New Neander's Medical

There is an antibody-dependent enhancement (ADE) of SARS-CoV-1 infection. Notably, some vaccines enhance infection.

Fig. 2. Model of immunopathological events associated with SARS clinical evolution. SARS patients mount robust IFN-mediated innate immune responses during early (acute) illness and peak symptomology. Following the median SO2 nadir in surviving patients (late SARS), most SARS patients resolve inflammation and mount effective adaptive immunity against SARS CoV. Immune dysregulation in severe SARS patients is hallmarked by continued expression of inflammatory chemokines and ISGs and deficiencies in MHC and Ig gene expression. Immune-mediated pathology worsens in the minority of susceptible SARS patients and unresolved CXCL10 expression and viral burden is associated with poor outcome. Source: Cameron, 2007.

Some vaccines against animal coronaviruses have been successfully generated, but their development has proven very difficult due to immune enhancement of disease in vaccinated recipients (28, 53, 65).